Literature DB >> 12781784

The effect on motor cortical neuronal development of focal lesions to the sub-cortical white matter in the neonatal rat: a model for periventricular leukomalacia.

Claire L Gibson1, Gavin J Clowry.   

Abstract

Periventricular leukomalacia (PVL) is either a diffuse or cystic lesion of the periventricular white matter that leaves the overlying cortical grey matter largely intact. It is believed to result from hypoxia occurring pre- or perinatally and is a major cause of cerebral palsy. We have modelled PVL in rats comparing the effects of discrete injections of 3-nitropropionic acid (3-NP), a mitochondrial toxin, ibotenic acid (IBA), a glutamate analogue, or saline into the sub-cortical white matter on postnatal day 7 (P7). Following recovery times ranging from 3 days to 4 weeks, forebrain sections were Nissl stained or immunostained for Bax, cJun, calbindin (CB), parvalbumin (PV) or non-phosphorylated neurofilaments (NPNF). Compared to saline injections, ibotenic acid caused large lesions of both grey and white matter not characteristic of periventricular leukomalacia. 3-Nitropropionic acid injections caused small focal lesions restricted to the sub-cortical white matter. 3-Nitropropionic acid treatment initially increased expression of the apoptosis promoting proteins Bax and cJun, as well as non-phosphorylated neurofilaments in cortical layer V overlying the injection site. Non-phosphorylated neurofilament expression distal to the lesion was decreased representing a loss of cortical axons, but persisted and even increased with time within the cortex, demonstrating persistence of the parent cell bodies and local sprouting of neurites. There were significantly fewer calbindin and parvalbumin positive neurones in the motor cortex (MC) side ipsilateral to the 3-nitropropionic acid injection compared to the contralateral side. These persistent differences in expression of activity sensitive calcium binding proteins suggest alterations in local cortical circuitry without substantial loss of grey matter as is characteristic of periventricular leukomalacia. Changes in expression of Bax, cJun and non-phosphorylated neurofilaments during normal development are also described.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781784     DOI: 10.1016/s0736-5748(03)00041-8

Source DB:  PubMed          Journal:  Int J Dev Neurosci        ISSN: 0736-5748            Impact factor:   2.457


  6 in total

1.  Animal models of developmental motor disorders: parallels to human motor dysfunction in cerebral palsy.

Authors:  Clarissa F Cavarsan; Monica A Gorassini; Katharina A Quinlan
Journal:  J Neurophysiol       Date:  2019-08-14       Impact factor: 2.714

2.  Gap junction networks can generate both ripple-like and fast ripple-like oscillations.

Authors:  Anna Simon; Roger D Traub; Nikita Vladimirov; Alistair Jenkins; Claire Nicholson; Roger G Whittaker; Ian Schofield; Gavin J Clowry; Mark O Cunningham; Miles A Whittington
Journal:  Eur J Neurosci       Date:  2013-10-14       Impact factor: 3.386

3.  Development and Validation of a Dynamic Nomogram to Predict the Risk of Neonatal White Matter Damage.

Authors:  Wenjun Cao; Chenghan Luo; Mengyuan Lei; Min Shen; Wenqian Ding; Mengmeng Wang; Min Song; Jian Ge; Qian Zhang
Journal:  Front Hum Neurosci       Date:  2021-02-23       Impact factor: 3.169

Review 4.  Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia.

Authors:  Zhihong Jiang; Rita M Cowell; Kazu Nakazawa
Journal:  Front Behav Neurosci       Date:  2013-09-03       Impact factor: 3.558

Review 5.  What are the Best Animal Models for Testing Early Intervention in Cerebral Palsy?

Authors:  Gavin John Clowry; Reem Basuodan; Felix Chan
Journal:  Front Neurol       Date:  2014-12-04       Impact factor: 4.003

6.  Establishing a rat model of spastic cerebral palsy by targeted ethanol injection.

Authors:  Yadong Yu; Liang Li; Xinzhong Shao; Fangtao Tian; Qinglu Sun
Journal:  Neural Regen Res       Date:  2013-12-05       Impact factor: 5.135

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.